Showing 3351-3360 of 6035 results for "".
- Tickets and Sponsorships Available for 2026 Prevent Blindness Person of Vision Award Gala Honoring Jim McGrannhttps://modernod.com/news/tickets-and-sponsorships-available-for-2026-prevent-blindness-person-of-vision-award-gala-honoring-jim-mcgrann/2485427/Prevent Blindness has announced that tickets and sponsorship opportunities remain available for the 2026 Prevent Blindness Person of Vision Award gala, which will honor Jim McGrann, CEO of Advancing Eyecare, for his decades of leadership and dedication to improving
- Vision Expo 2026 Marks 40 Years With Expanded Education Experiencehttps://modernod.com/news/vision-expo-2026-marks-40-years-with-expanded-education-experience/2485286/Produced by RX and The Vision Council, Vision Expo is celebrating its 40th year in 2026 with an enhanced educational conference designed to deliver greater access, flexibility and real-world learning for vision care professionals.
- Oculis Prices $110 Million Financing to Accelerate Privosegtor Developmenthttps://modernod.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/Oculis announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary shares at a price of $20.25 per share for total gross proceeds of $110 million. The net proceeds from the financing will be used to advance and accelerate the d
- Eli Lilly Enters Ophthalmology Sector with Acquisition of Adverum Biotechnologieshttps://modernod.com/news/eli-lilly-enters-ophthalmology-sector-with-acquisition-of-adverum-biotechnologies/2484212/Eli Lilly and Company and Adverum Biotechnologies announced that they have entered into a definitive agreement for Lilly to acquire Adverum Biotechnologies, including its lead gene therapy product candidate, Ixo-vec. I
- FDA Issues CRL to Sydnexis for SYD-101 in Pediatric Myopiahttps://modernod.com/news/fda-does-not-approve-sydnexis-syd-101-in-pediatric-myopia/2484210/The FDA has issued a complete response letter (CRL) for Sydnexis' new drug application (NDA) for SYD-101, a proprietary 0.01% atropine formulation designed to slow the progression of myopia in children. T
- Astellas Announces New Data Demonstrating Long-Term Efficacy of Izervay in Slowing GA Progressionhttps://modernod.com/news/astellas-announces-new-data-demonstrating-long-term-efficacy-of-izervay-in-slowing-ga-progression/2484199/Astellas Pharma announced the first results from the open-label extension (OLE) trial of the phase 3 GATHER2 study, which showed that monthly treatment with Izervay (avacincaptad pegol intravitreal solution) continued to slow disease progression in patie
- Formycon Expands Global Reach of Eylea Biosimilar FYB203 with Licensing Deals in Australia and Latin Americahttps://modernod.com/news/formycon-expands-global-reach-of-eylea-biosimilar-fyb203-with-licensing-deals-in-australia-and-latin-america/2484186/Formycon AG announced that its licensing partner Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea¹ biosimilar FYB203 (aflibercept), has signed two new exclusive agreements to broaden the product’s internat
- Rayner Secures FDA Approval for RayOne EMV Toric IOLhttps://modernod.com/news/rayner-secures-fda-approval-for-rayone-emv-toric-iol/2484172/The FDA has approved Rayner's RayOne EMV Toric IOL following the completion of a pivotal investigational device exemption (IDE) study. According to Rayner, the RayOne EMV Toric lens has been enginee
- EyeDura Therapeutics Partners with SERI to Advance Insulin-Based Topical Therapy for Neurotrophic Keratitishttps://modernod.com/news/eyedura-therapeutics-partners-with-seri-to-advance-insulin-based-topical-therapy-for-neurotrophic-keratitis/2484157/EyeDura Therapeutics has initiated preclinical efficacy studies in collaboration with the Singapore Eye Research Institute (SERI). The studies will advance the company’s lead insulin-based eye drop treatment for neurotrophic keratitis (NK), a rare, degen
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph